Literature DB >> 8898430

Helicobacter pylori and peptic ulcer disease.

R W Van der Hulst1, G N Tytgat.   

Abstract

Helicobacter pylori is associated with diffuse superficial gastritis and is one of the dominant causal factors for duodenal ulcer disease. More recent knowledge has revealed that apart from NSAID-related ulcers, H. pylori is also highly associated with gastric ulcer disease. Follow-up of duodenal ulcer patients has revealed that the prevalence of duodenal ulcer relapse was sharply diminished after successful cure of H. pylori infection. The few data available concerning relapse rates of gastric ulcer disease indicate a striking reduction of recurrence of gastric ulceration after successful eradication of H. pylori. One of the most intriguing questions is why only a small percentage of H. pylori-infected patients develop peptic ulcer disease. The most recent literature is discussed concerning subtypes of H. pylori and virulence factors, making one H. pylori strain more pathogenic compared to the other. In addition, literature is discussed concerning the question whether gastric and duodenal ulcer disease are two different entities, or whether they are at opposite sites of one disease spectrum. Finally, the most current anti-H. pylori-treatment modalities are summarized.

Entities:  

Mesh:

Year:  1996        PMID: 8898430

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  10 in total

1.  Deceleration in the age pattern of mortality at older ages.

Authors:  S Horiuchi; J R Wilmoth
Journal:  Demography       Date:  1998-11

2.  cagA-positive Helicobacter pylori populations in China and The Netherlands are distinct.

Authors:  A van der Ende; Z J Pan; A Bart; R W van der Hulst; M Feller; S D Xiao; G N Tytgat; J Dankert
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

3.  Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia.

Authors:  Z J Pan; R W van der Hulst; M Feller; S D Xiao; G N Tytgat; J Dankert; A van der Ende
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications.

Authors:  P Bechi; S Bacci; F Cianchi; A Amorosi; G Nesi; R Dei; P Romagnoli
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

5.  Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication.

Authors:  R W van der Hulst; A van der Ende; A Homan; P Roorda; J Dankert; G N Tytgat
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

6.  Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication.

Authors:  K Iijima; S Ohara; H Sekine; T Koike; K Kato; S Asaki; T Shimosegawa; T Toyota
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

7.  A role for CagA/VacA in Helicobacter pylori inhibition of murine duodenal mucosal bicarbonate secretion.

Authors:  Bi-Guang Tuo; Zachary M Sellers; Anders J Smith; Kim E Barrett; Jon I Isenberg; Hui Dong
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 8.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Difference in the distribution pattern of Helicobacter pylori and grade of gastritis in the antrum and in the body between duodenal ulcer and benign gastric ulcer patients.

Authors:  N Kim; W R Choi; C H Song; D H Sheen; S S Yang; J Y Lee; Y J Han; S H Lim; K H Lee; S E Choi
Journal:  Korean J Intern Med       Date:  2000-01       Impact factor: 2.884

10.  Effect of eradication of Helicobacter pylori on the benign gastric ulcer recurrence--a 24 month follow-up study.

Authors:  N Kim; J H Oh; C G Lee; C Lim; K H Won; W R Choi; S H Lee; S H Lim; K H Lee
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.